Why did the 4588.T stock fall so sharply today?

The intraday fall of **-20.65%** to **JPY 2,175.00** followed concentrated selling, higher relative volume and renewed attention to valuation metrics. Thin liquidity and profit-taking after recent gains likely accelerated the move.

What is Meyka AI’s outlook for 4588.T stock?

Meyka AI rates 4588.T **67.85/100 (B, HOLD)**. The model projects **JPY 2,533.49** monthly (+16.49%) and **JPY 603.23** yearly (-72.29%). These are scenario-based forecasts, not guarantees.

Which financial ratios matter for 4588.T stock now?

Watch **EPS -93.19**, **PE -28.01**, **price/book 14.41**, and **cash per share JPY 144.67**. High R&D spend (**51.51%** of revenue) and strong current ratio signal runway but elevated market valuation increases risk.

What triggers should traders watch for 4588.T stock?

Key triggers are clinical trial updates for Telomelysin, the earnings announcement on **08 May 2026**, and any funding or licensing news. Changes in daily volume or movement through **JPY 2,098.05** (Bollinger lower) matter for intraday risk.

JP Stocks

4588.T Oncolys (JPX) down 20.65% intraday 18 Mar 2026: model target and risks

ByDanny Kontos March 18, 2026March 18, 2026

The 4588.T stock plunged -20.65% intraday to JPY 2,175.00 on JPX on 18 Mar 2026 after heavy selling from the previous close of JPY 2,741.00. Traders flagged thin liquidity and profit-taking around recent gains. Volume reached 770,300 shares versus a 50‑day average of 2,875,649.00, increasing intraday volatility. We review fundamentals, technicals, Meyka AI’s grade and forecast, and scenario price targets to help assess whether this drop creates a trading entry or a warning signal.